Board of Directors
On June 16, 2017, GENFIT’s shareholders voted to change the mode of administration of the Company from a Société Anonyme with an Executive Board and Supervisory Board to a Société Anonyme with a Board of Directors.
The Board of Directors subsequently appointed Jean-François Mouney as its Chairman and Xavier Guille des Buttes as its Vice-chairman.
The Company is managed by a Board of Directors composed of seven members, five of whom the Board has determined are independent under the Middlenext Corporate Governance Code adopted by the Company.
In addition, the Board of Directors formed two specialized committees: the Audit Committee and Nominations and Compensation Committee. These Committees provide specialist input to assist the Board in its decision-making process. Their members are chosen by the Board from among its members, based on their experience.
Xavier Guille Des Buttes
Vice-Chairman of the Board of Directors, Chairman of the Nomination and Compensation Committee, Member of the Audit Committee
Graduated from the ESSCA (Ecole Supérieure des Sciences Commerciales d’Angers), from the Institute of Foreign Commerce and from the Management Control Institute, Xavier Guille des Buttes has spent his entire career in the pharmaceutical industry. He has held a large number of executive positions for more than 30 years, particularly in the French subsidiary of the German Group Schering AG, and most recently Chairman of the Management Board until June 2006.
Member of GENFIT’s Supervisory Board since 2006, he was chairman from 2008 until he was appointed Vice-Chairman of the Board of Directors of GENFIT following a change in the mode of administration on June 16, 2017. In addition to his responsibilities at GENFIT, he also serves as director of several companies. He holds offices with Atlanta (a start-up based in Nantes), Delpharm Holding (pharmaceutical manufacturing), Hemarina, a start-up located in Morlaix and Medsenic (start-up based in Strasbourg).
Xavier Guille Des Buttes also chairs the Foundation of the Catholic University of Lille and is a knight of the Legion of Honor.
Dr. Catherine Larue
Member of the Nomination and Compensation Committee
Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016.
From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at GENFIT until 2012. Dr. Catherine Larue began her career as an R&D team leader at Sanofi in the cardiovascular research department. She later joined Sanofi Diagnostics Pasteur in particular as Director, and then spent 11 years at the Bio-Rad group, holding different management positions. She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products.
Dr. Catherine Larue holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John’s University (New York).
Chairman of the Audit Committee
Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management.
Since 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels. In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. She has extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector.
Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013.
Frédéric Desdouits is head of Pierre Fabre Group Business Development, Acquisition and Market Intelligence since 2011. He is also member of the Pharmaceuticals Executive Board and of the Development Products Board. Prior to joining Pierre Fabre, Frederic was Managing Partner at Bionest Partners and the founding Managing Partner of Bionest Partners Finance, a consulting and transaction firm based in Paris and New York specialized in healthcare and biotechnologyand value strategy for emerging bio-companies. Before continuing in finance at Exane BNP Paribas, Frédéric worked in research in several large pharmaceutical groups including GlaxoWellcome in France (now GSK) and Hoechst.
Frédéric Desdouits is a member of the Supervisory Board of CiToxLab and board observer on the Board of Directors of Orphelia Pharma.
Frédéric Desdouits graduated from École Polytechnique (Palaiseau, France), obtained a MS in pharmacology and a PhD in Neurosciences at University Paris VI and Collège de France, did a post-doc (1994-1996) at the Rockefeller University in New York. He is a CEFA (Certified European Financial Analyst) and Certified in Global Management from INSEAD.
Graduated from the École des Mines of Paris (Biotechnology option) and holding a master degree in Pharmacy from the University of Illinois (Chicago, United States), she was in charge of the biopharmaceutical sector for Eurasanté.
She co-founded GENFIT and served as the Company’s Chief Operating Officer, Business Development Director, industrial alliances coordinator and member of the Executive Board from 1999 to 2008. Since then, she is Chairman of the Company Da Volterra.
Member of the Audit Committee
Graduated from the Institut Catholique des Arts et Métiers de Lille and from the Ecole des Hautes Etudes Commerciales du Nord (EDHEC), Philippe Moons began his career as a business engineer in a French industrial Group. In 1995, he joined Finorpa, a venture capital and growth capital company, operating under the aegis of the Group “Charbonnage de France” and of the Nord-Pas-de-Calais region. Since 2006, he is in charge of supporting and financing several companies in their early-stage activities or development phases; in particular in the fields of biology and health.
In addition to his current responsibilities at Finorpa and GENFIT, where he serves as a corporate director, Philippe Moons is a member of the Supervisory Board of Finovam, a regional venture capital company, established in 2014 to strengthen the emergence and provide seed capital to innovative businesses, primarily technological projects in the Nord-Pas-de-Calais region.